*These authors contributed equally to the study.
Article first published online: 30 NOV 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 54, Issue 6, pages 2089–2098, December 2011
How to Cite
Olaru, A. V., Ghiaur, G., Yamanaka, S., Luvsanjav, D., An, F., Popescu, I., Alexandrescu, S., Allen, S., Pawlik, T. M., Torbenson, M., Georgiades, C., Roberts, L. R., Gores, G. J., Ferguson-Smith, A., Almeida, M. I., Calin, G. A., Mezey, E. and Selaru, F. M. (2011), MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology, 54: 2089–2098. doi: 10.1002/hep.24591
Potential conflict of interest: Nothing to report.
This work was supported by an American Gastroenterological Association grant to F.M.S. (Fellowship to Faculty Transition Award), by a Flight Attendants Medical Research Institute (FAMRI) grant (072119_YCSA) to F.M.S., by the Johns Hopkins Clinician Scientist Award to F.M.S., by a Pilot Project from the The Hopkins Conte Digestive Diseases Basic & Translational Research Core Center to F.M.S., and by a K08 Award (DK090154-01) from the NIH to F.M.S.
- Issue published online: 30 NOV 2011
- Article first published online: 30 NOV 2011
- Accepted manuscript online: 1 AUG 2011 08:17AM EST
- Manuscript Accepted: 20 JUL 2011
- Manuscript Received: 6 MAY 2011
MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes. In the current study we aimed at elucidating regulatory pathways and mechanisms through which miR-494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), participates in cancer homeostasis. miR-494 was identified as down-regulated in CCA based on miR arrays. Its expression was verified with quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). To enforce miR expression, we employed both transfection methods, as well as a retroviral construct to stably overexpress miR-494. Up-regulation of miR-494 in cancer cells decreased growth, consistent with a functional role. mRNA arrays of cells treated with miR-494, followed by pathway analysis, suggested that miR-494 impacts cell cycle regulation. Cell cycle analyses demonstrated that miR-494 induces a significant G1/S checkpoint reinforcement. Further analyses demonstrated that miR-494 down-regulates multiple molecules involved in this transition checkpoint. Luciferase reporter assays demonstrated a direct interaction between miR-494 and the 3′-untranslated region of cyclin-dependent kinase 6 (CDK6). Last, xenograft experiments demonstrated that miR-494 induces a significant cancer growth retardation in vivo. Conclusion: Our findings demonstrate that miR-494 is down-regulated in CCA and that its up-regulation induces cancer cell growth retardation through multiple targets involved in the G1-S transition. These findings support the paradigm that miRs are salient cellular signaling pathway modulators, and thus represent attractive therapeutic targets. miR-494 emerges as an important regulator of CCA growth and its further study may lead to the development of novel therapeutics. (HEPATOLOGY 2011)